Overwhelming data suggest that GR signaling can drive tumor proliferation and even neuroendocrine differentiation under enzalutamide treatment.[22,23] However, this is unlikely to be a major clinical problem for most other patients. The gene discussed is NR3C1; the disease is neoplasm.